Iambic closed an oversubscribed $100 million financing to advance its AI platforms — Enchant for clinical endpoint prediction and NeuralPLexer for protein-ligand structure forecasts — and accelerate oncology candidates into the clinic. The company said its Enchant model helps evaluate clinical viability early while NeuralPLexer improves protein-structure predictions, and cited a collaboration with Revolution Medicines to customize models. Iambic also disclosed clinical activity for lead candidate IAM1363, a brain‑penetrant HER2 inhibitor showing early signs of tumor activity. The financing will expand R&D, bespoke partner models, and downstream CRO efforts to move candidates toward INDs. The round reflects growing investor appetite for companies that pair physics-informed ML with generative models to shrink preclinical cycles and de-risk translational decision‑making in oncology.